18 February 2021
blog
10 February 2021
Adjuvant Leads $6 million Series B for Frontier Nutrition
Read Article22 January 2021
MinervaX Raises Upsized €47.4 Million Series B for Novel GBS Vaccine Candidate
Read Article26 October 2020
The Power Of Choice
Read Article25 August 2020
Henry Ford Didn’t Invent the Assembly Line
Read Article25 August 2020
Rabies Restock
Read Article18 June 2020
Let’s Do More With Less
Read Article26 May 2020
The Platform That Was Promised
Read Article11 May 2020
Perfecting Detecting
Read Article14 April 2020
Genomics’ Missing Puzzle Piece
Read Article20 March 2020
Adjuvant Adds Third COVID-19 Intervention to its Portfolio
Read Article13 February 2020
Codagenix Teams Up with World’s Largest Vaccine Manufacturer to Mount a COVID-19 Response
Read Article30 January 2020
Deoptimize This
Read Article13 January 2020
Adjuvant Leads $20 Million Series B for Codagenix, Inc.
Read Article21 November 2019
Melioidosis: Ever Heard of it?
Read Article18 September 2019
Reprogramming a 50-Year-Old Vaccine to Tackle a Sprawling List of Modern Diseases
Read Article10 September 2019
Bringing Biologic Potency Testing into the 21st Century
Read Article23 July 2019
“Beating Herpes”: Adjuvant’s First Investment Targets a Daunting Viral Infection
Read Article04 June 2019
CEPI Awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
Read Article15 May 2019
Lilly deSouza Burr Joins the Adjuvant Capital Team in New York
Read Article01 October 2018